CDK4 and breast carcinoma: In addition to HR+ breast cancer cells, abemaciclib treatment significantly increased lysosomal content and sensitivity to lysosomotropic agents in MDA-MB-231 cells, a TNBC cell line that is responsive to CDK4/6 inhibition.